Description: ProQR Therapeutics B.V., a biopharmaceutical company, is engaged in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.
Home Page: www.proqr.com
PRQR Technical Analysis
Zernikedreef 9
Leiden,
2333 CK
Netherlands
Phone:
31 88 166 7000
Officers
| Name | Title |
|---|---|
| Dr. Domenico Valerio Ph.D. | Founder & Independent Chairman of Supervisory Board |
| Mr. Daniel Anton de Boer | Founder, CEO & Member of Management Board |
| Dr. Gerard Platenburg | Co-Founder & Chief Scientific Officer |
| Mr. Jurriaan Dekkers | Chief Financial Officer |
| Mr. Rene K. Beukema | Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board |
| Ms. Sheila Sponselee | VP & Head of People and Operations |
| Ms. Sarah Cue Kiely | VP of Investor Relations & Corp. Communications |
| Mr. Bart Klein | Sr. VP of Intellectual Property |
| Mr. Aniz Girach M.D. | Chief Medical Officer |
| Ms. Sandra van der Kolk | Jr. Financial Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7016 |
| Price-to-Sales TTM: | 29.2419 |
| IPO Date: | 2014-09-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 181 |